M28 Capital Management LP

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
M28 Capital Management LP
CRD #307490
SEC #801-126182
CIK #0001807489
AUM
Employees 3 (33% Investors, 0% Brokers)
Fees
Minimum
Phone203-516-3730
Address700 Canal Street
Stamford, CT 06902
Source [IAPD] [EDGAR] [Website]
Total AUM ($M)
16012896643202010201520212027
Fees and Compensation — Form ADV Part 2A (3/25/2025) [Brochure]
Fees and Compensation

A.      Advisory Services and Fees

     1. The Funds

M28 Capital, either directly or indirectly through affiliated entities, receives management and
performance-based incentive allocations in connection with the investment advisory services M28
Capital provides to the Funds. The fees and/or allocations applicable to each Fund are set forth in
detail in the Offering Documents.

A brief summary of such fees and allocations for the Funds is provided below.

Management Fee

Investors in the Funds (“Fund Investors”) generally are charged a management fee that ranges
between 1.50% and 1.75% per annum (the “Management Fee”) of each Fund Investor’s capital
account balance as of the beginning of the month, subject to certain reductions as fully set forth in
the Offering Documents.

M28 Capital and/or the Fund General Partner, in its sole discretion, may reduce, waive or modify
the Management Fee for certain Fund Investors, where applicable.

Incentive Allocation

At the end of each fiscal year, the Fund General Partner will be entitled to receive an incentive
allocation based on the investment performance of the Funds (the “Incentive Allocation”)
generally in an amount between 15% and 20% of realized and unrealized gains (excluding
unrealized gains on Designated Investments) for the year subject to a traditional “high watermark”
and subject to certain reductions as fully set forth in the Offering Documents. The Incentive
Allocation for Designated Investments is calculated upon the realization of such investments.

M28 Capital and/or the Fund General Partner, in its sole discretion, may reduce, waive or modify
the Incentive Allocation for certain Investors, where applicable.

The Fund General Partner or an affiliate have waived the Management Fee and Incentive
Allocation for itself and its partners, affiliates, employees, and family members. In addition, the
Funds occasionally enter into “side letter” arrangements or similar agreements with certain
Investors which grant such Investors with different or additional terms. These terms include, but
are not limited to, different or more favorable fees charged, minimum subscription amounts,
redemption rights and other rights.

     2. Co-Investment Vehicles

Management fees, incentive allocations, and incentive fees applicable to Co-Investment Vehicles
are generally negotiated at the time of the co-investment opportunity between M28 Capital and the
co-investors. Such fees and allocations are set forth in detail in the applicable Co-Investment
Vehicle’s Offering Documents and likely will differ from those compensation arrangements
otherwise applicable to other Fund Investors.

B.       Payment of Fees

With respect to the Funds, Management Fees are paid monthly in advance. Incentive Allocations
are paid annually in arrears (excluding unrealized gains on Designated Investments). With respect
to the Funds, the Management Fee and Incentive Allocation are generally deducted from each
Investor’s capital balance account by the Funds’ administrator.

C.       Additional Expenses

In addition to the fees and allocations described above, each Fund generally bears all of their own
expenses, including but not limited to expenses related to its operations and the investment of its
assets. Each Fund shall bear those expenses as set forth in the applicable Offering Document, as
amended from time to time, including, but not limited to, some or all of the following:

     •   Organizational and offering expenses;
     •   Expenses associated with sourcing, negotiating, investigating, researching, financing and
         structuring of investments and potential investments, whether or not consummated,
         including, without limitation, third-party research, data, analytics, modeling, risk,
         structuring, pricing, execution and other third-party information systems, including,
         without limitation, installation and maintenance, software and service fees (including,
         without limitation, the expenses with respect to data, data feeds, subscriptions, expert
         networks, political intelligence providers and reports);
     •   The costs of research-related computer hardware and software expenses, including, without
         limitation, Bloomberg terminals and subscriptions;
     •   The costs of M28 Capital’s portfolio management system and any other software used for
         accounting and/or monitoring of the portfolio, including, without limitation, subscriptions
         relating to, among other things, trading and order management systems and services;
     •   Expenses associated with holding, financing, monitoring, hedging, maintaining and
         disposing of all investments of the Funds and all transaction and other costs associated
         therewith;
     •   Travel and related expenses associated with investments and potential investments;
     •   Professional fees associated with investments and potential investments, including, without
         limitation, consulting, due diligence, accounting, valuation, financial, legal and other
         advisory fees and expenses;

•   Transaction fees, brokerage commissions, custodial fees, clearing and settlement charges
    and similar fees and expenses associated with the acquisition, disposition and settling of
    investments and potential investments;
•   Expenses associated with legal and regulatory filings of the Funds;
•   Administrative, custodial, appraisal, valuation, legal, regulatory, compliance, consulting,
    advisory and similar fees and expenses associated with the Funds’ operations, investments
    and transactions, including, without limitation, fees and expenses of the administrator;
•   Expenses incurred in connection with responding to requests or inquiries from any U.S.
    federal, state, local or non-U.S. governmental entity or authority, regulatory body or self-
    regulatory organization with respect to the Funds;
...
Account Minimums and Types of Clients — Form ADV Part 2A (3/25/2025) [Brochure]
Types of Clients

M28 Capital provides investment advisory services to the Funds and Co-Investment Vehicles, as
described above.

Fund Investors may, among others, include institutions, pension plans, endowments, foundations,
trusts, high net-worth individuals, financially sophisticated individuals, and other sophisticated
investors. The Funds typically require a minimum initial investment of $5,000,000, subject to the
discretion of M28 Capital and/or the Fund General Partner to accept a lower amount. Investors
generally must be “Accredited Investors” and “Qualified Purchasers” (as defined under federal
securities laws).
Sector Form 13F Holdings Value ($M)
Wave Life Sciences Ltd 33.3
Adagio Therapeutics Inc 12.0
Manhattan Pharmaceuticals Inc 2.9
Arrowhead Research Corp 2.3
Proqr Therapeutics NV 1.0
Fractyl Health Inc 0.8
Inotek Pharmaceuticals Corp 0.8
Silence Therapeutics PLC 0.5
Curis Inc 0.2
 
 
Holdings by Sector ($M)
14011284562802020202220242027
Type Form D Funds Date Sold AUM
VC Sparviero LP 2022-03-30 0.9 M
VC Veltro Argento LP [2020-08-06] 0.7 M
Filed 2020-06-10 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
HF M28 Capital Master Fund LP [2020-05-01] 14.2 M 117.5 M
Filed 2024-03-29 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 6 120.8
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 6 120.8
By Discretionary
Discretionary 6 120.8
Non-Discretionary 0 0.0
Total 6 120.8
By Non-United States Persons
Non-United States Persons 117.5
United States Persons 3.3
Total 6 120.8
Form D Directors Role # Filings # Firms 2011 - 2026
Geoff Ruddick Director 256 66
Yolanda Banks McCoy Director 46 18
Laura McGeever Director 33 12
Marc Elia Executive Officer 11 2
M28 Capital Fund GP LLC Executive Officer 4 2
Chris Taliercio Executive Officer 4 2
M28 Capital Management LP Executive Officer 4 2
EDGAR Form CIK 2011 - 2026
13F-HR [0001807489]
3 [0001807489]
4 [0001807489]
SC 13D [0001807489]
SC 13G [0001807489]
Form 13D/13G Filer Form 13D/13G Subject Filed
M28 Capital Management LP Curis Inc [2024-02-12]
M28 Capital Management LP Adagio Therapeutics Inc [2022-04-01]
M28 Capital Management LP Wave Life Sciences Ltd [2021-10-29]
M28 Capital Management LP Adagio Therapeutics Inc [2021-10-05]
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund
LEI54930021KW24ME6P6555
Form 3/4/5 Subject 2011 - 2026
Elia Marc
M28 Capital Management LP
Invivyd Inc
Fractyl Health Inc
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Invivyd Inc IVVD
Stock Option (Right to Buy) · derivative
2025-05-20 Grant 50,000 $0.00
Invivyd Inc IVVD
Stock Option (Right to Buy) · derivative
2024-05-21 Grant 50,000 $0.00
Fractyl Health Inc GUTS
Common Stock
2024-02-06 Conversion 1,389,451
Fractyl Health Inc GUTS
Common Stock
2024-02-06 Buy 466,666 $15.00 6,999,990
Fractyl Health Inc GUTS
Series F Preferred Stock · derivative
2024-02-06 Conversion 2,981,763
Invivyd Inc IVVD
Stock Option (Right to Buy) · derivative
2023-05-23 Grant 50,000 $0.00
Invivyd Inc ADGI
Common Stock
2022-08-19 Buy 584,451 $4.62 2,700,164
Invivyd Inc ADGI
Common Stock
2022-08-18 Buy 1,265,549 $4.31 5,454,516
Invivyd Inc ADGI
Common Stock
2022-08-17 Buy 1,000,000 $4.04 4,040,000
Invivyd Inc ADGI
Stock Option (Right to Buy) · derivative
2022-06-22 Grant 150,000 $0.00
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com